Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYLINE: Gantenerumab in early Alzheimer's disease
NCT05256134Phase 3Terminated
- Sponsor
- Roche
- Start
- Apr 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of gantenerumab in Alzheimer's disease (AD), sponsored by Roche. Started Apr 2022; status: terminated.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05256134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256134.